HuR-Targeted Small-Molecule Inhibitors─Beneficial Impact in Cancer Therapy

Small-molecule inhibitors have become a major therapeutic class for cancer treatment. A growing body of evidence sheds light on HuR in cancer progression. HuR is an RNA-binding protein involved in all post-transcriptional regulation mechanisms dictating the transcript's fate in the cell. This prompted scientists to develop HuR-targeted small-molecule inhibitors (SMIs). Due to its advantages, targeted therapy using SMIs has entered an era where it accelerates the potential of cancer treatment. This account summarizes the role of HuR in cancer progression and the effect of known SMIs targeting HuR in numerous cancers, emphasizing the perspectives in this field.